Showing 3071-3080 of 6035 results for "".
- Fact.MR Highlights Accelerating Sales of Corrective Lenses; Contact Lens Market Set to Record 5% Through 2029https://modernod.com/news/fact-mr-highlights-accelerating-sales-of-corrective-lenses-contact-lens-market-set-to-record-5-through-2029/2477317/The proliferation of visually-impaired consumers and their participation in outdoor activities, coupled with increasing cases of myopia, presbyopia, and astigmatism, will drive the global contact lens market to witness a staggering growth trajectory of over 5% between 2019 and 2029, according to
- Expanding Product Needs, Surgery Growth Will Drive Retinal Surgical Device Market to Nearly $2 Billion by 2025https://modernod.com/news/expanding-product-needs-surgery-growth-will-drive-retinal-surgical-device-market-to-nearly-2-billion-by-2025/2477308/Ophthalmologists use more specialized products in retinal surgeries than other subspecialties, producing more revenue per procedure than segments with higher surgical volume. As a result, the retinal surgical device market is expected to total more than $1.57 billion in 2020, with revenue rising
- Myopia Management Focus of Pipeline Expansion for Leo Lens Pharmahttps://modernod.com/news/myopia-management-focus-of-pipeline-expansion-for-leo-lens-pharma/2477307/Leo Lens Pharma (formerly DBA as Leo Lens Technology Co.) announced it received a notice of allowance from the United States Patent and Trademark Office for a patent for the use of its proprietary MediPrint process to manufacture a contact lens capable of providing enhance
- Gyroscope Therapeutics Strengthens Senior Leadership Ahead of Next Stage of Company Growthhttps://modernod.com/news/gyroscope-therapeutics-strengthens-senior-leadership-ahead-of-next-stage-of-company-growth/2477297/Gyroscope Therapeutics announced the strengthening of its leadership team with the hiring of Nadia Waheed, MD, MPH, from Tufts University School of Medicine in Boston as Chief Medical Officer (CMO), and the promotion of Jane Hughes, PhD, formerly VP Translational Research, to Chief Scientific Off
- Ocular Therapeutix Presents Data Demonstrating a Reduction in IOP in Patients Treated with OTX-TIChttps://modernod.com/news/ocular-therapeutix-presents-data-demonstrating-a-reduction-in-iop-in-patients-treated-with-otx-tic/2477290/Ocular Therapeutix presented data on OTX-TIC, a long acting travoprost intracameral implant for the treatment of patients with primary open angle glaucoma or ocular hypertension. Data from this phase 1 clinical trial demonstrated a clinically-meaningful reduction in IOP for up to 18 months in the
- Lineage Provides Positive Update on Phase 1/2a Clinical Study of OpRegen for the Treatment of Dry Age-Related Macular Degenerationhttps://modernod.com/news/lineage-provides-positive-update-on-phase-i-iia-clinical-study-of-opregen-for-the-treatment-of-dry-age-related-macular-degeneration/2477278/Lineage Cell Therapeutics a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today provided an update from its ongoing phase 1/2a clinical study of OpRegen, the company’s retinal pigment epithelium (RPE) transplant therapy, for the treatment of dry
- Staar Surgical Announces the EVO Implantable Lens US Clinical Trial is Underwayhttps://modernod.com/news/staar-surgical-announces-the-evo-implantable-lens-us-clinical-trial-is-underway/2477273/Staar Surgical announced the first patient was implanted in the company’s US human clinical study for its EVO ICL family of lenses. The investigational study, “A Multicenter Clinical Evaluation of the EVO/EVO+ Visian Implantable Collamer Lens,” will be conducted at more than a dozen ophthalmology
- ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421ahttps://modernod.com/news/proqr-receives-rare-pediatric-disease-designation-from-fda-for-qr-421a/2477267/ProQR Therapeutics announced that it received Rare Pediatric Disease (RPD) designation from the FDA for QR-421a for the treatment of patients with retinitis pigmentosa caused by mutations in exon 13 of the USH2A gene. QR-421a is a first-in-class investigational RNA-based oligonucl
- EyePoint Pharmaceuticals and Ocumension Therapeutics Sign License Agreement to Develop and Commercialize Dexycu in China, Hong Kong, Macau, and Taiwanhttps://modernod.com/news/eyepoint-pharmaceuticals-and-ocumension-therapeutics-sign-license-agreement-to-develop-and-commercialize-dexycu-in-china-hong-kong-macau-and-taiwan/2477260/EyePoint Pharmaceuticals and Ocumension Therapeutics announced an exclusive license agreement for the development and commercialization of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammation following ocular surgery in Mainland China, Hong Kong, Macau
- Alexander van der Mey Named New CCO at Optimo Medical AGhttps://modernod.com/news/alexander-van-der-mey-named-new-cco-at-optimo-medical-ag/2477248/As of January 16, Alexander van der Mey assumed the role of chief commercial officer (CCO) position of Optimo Medical AG. In his new position, Mr. van der Mey is responsible for global marketing and sales. Mr. Van der Mey has studied business administration in Germany and the Netherlands.